Cerenome is trading 6.2% down at $1.63, with broader risk sentiment potentially contributing; no clear company-specific catalyst has been identified for October 14, 2026. - Its latest listed company announcements were the October 6 test launch and October 8 Florida Blue agreement; neither is new news explaining the decline. - Hotter-than-expected September inflation lifted rate-hike concerns, and Reuters reported U.S. stock futures turned negative after the CPI release. - The S&P 500 and Nasdaq were down, while healthcare was higher.